Search results for "CARDIOVASCULAR DISEASE."

showing 10 items of 2331 documents

0470 : Serum IF1 concentration as a predictor of mortality in coronary heart disease patients

2015

Aim The ecto-F1-ATPase/P2Y13 pathway plays a key role in reverse cholesterol transport. Exogenous IF1, known as the natural mitochondrial specific inhibitor of F1-ATPase activity, inhibits ecto-F1-ATPase activity and decreases HDL-C uptake by hepatocytes. We previously found that IF1 is present in human serum and is negatively associated with coronary heart disease (CHD). Here, we investigated the relationship between serum IF1 concentration and mortality in CHD patients. Methods Serum IF1 was measured in 624 CHD patients aged 45-74 from the GENES (Genetique et ENvironement en Europe du Sud) study. After 9.1 years follow up, mortality rate was 24.5%. Results Patients who had died were older…

medicine.medical_specialtyEjection fractionbusiness.industryMortality rateReverse cholesterol transportmedicine.diseaseCoronary heart diseaseEndocrinologyAtheromaQuartileInternal medicineDiabetes mellitusCardiologyMedicinecardiovascular diseasesCardiology and Cardiovascular MedicinebusinessDyslipidemiaArchives of Cardiovascular Diseases Supplements
researchProduct

0283: Correlation between N-terminal pro-natriuretic peptide levels and left atrial size in patients with left ventricular systolic dysfunction

2014

BackgroundElevated N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP) levels are correlated with the severity of left ventricular systolic dysfunction and left ventricular filling alterations. Besides, left atrial (LA) size is believed to reflect chronic diastolic dysfunction.AimEvaluate the relationship between NT Pro-BNP and LA size.Methods81 patients (77.7% males; mean age, 61.55±15 years), with left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] 20cm2 was 1188pg/mL (area under the receiver-operating characteristic curve [AUC] 0.83 [0.71–0.93], p<0.0001, sensitivity 77.6%, specificity 75%).ConclusionThe present study shows that plasma NT Pro-BNP levels is…

medicine.medical_specialtyEjection fractionmedicine.drug_classbusiness.industryDiastoleMean ageEndocrinologyLeft atrialInternal medicineNatriuretic peptidemedicineCardiologycardiovascular systemIn patientcardiovascular diseasesCardiology and Cardiovascular MedicinebusinessVentricular fillingArchives of Cardiovascular Diseases Supplements
researchProduct

Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.

2019

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseasePrimary careType 2 diabetesurologic and male genital diseasesGlobal HealthDiabetic nephropathy03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsDiabetic Nephropathies030212 general & internal medicineIntensive care medicineNutrition and DieteticsPrimary Health Carebusiness.industryType 2 Diabetes Mellitusmedicine.diseaseClinical trialSurvival RateDiabetes Mellitus Type 2Cardiovascular DiseasesMorbidityFamily PracticebusinessKidney diseasePrimary care diabetes
researchProduct

The diabetogenic action of statins — mechanisms and clinical implications

2015

Treatment with statins has transformed primary and secondary prevention of cardiovascular disease (CVD), including thrombotic stroke. Evidence-based data demonstrate the benefits and safety of statin therapy and help to guide clinicians in the management of populations at high risk of CVD. Nevertheless, clinical trials, meta-analyses and observational studies highlight a 10-12% increase in new-onset diabetes mellitus (NODM) among patients receiving statins. The risk further increases with intensive therapy and among individuals with known risk factors for NODM. Mechanisms underpinning this effect are not yet fully understood; however, Mendelian randomization studies suggest that they are re…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesIn Vitro Techniques030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistancePharmacotherapyRisk FactorsInsulin-Secreting CellsDiabetes mellitusMendelian randomizationSecondary PreventionAnimalsHumansMedicinecardiovascular diseasesIntensive care medicinebusiness.industrynutritional and metabolic diseasesFeeding BehaviorMendelian Randomization Analysismedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesPhysical therapyHydroxymethylglutaryl CoA ReductasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessRisk Reduction BehaviorNature Reviews Endocrinology
researchProduct

Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial.

2014

Abstract Background and aim Post-menopausal women are at higher risk of cardiovascular disease and bone demineralization. Phytosterols (PS) may be used for hypercholesterolemia in some groups and β-cryptoxanthin (β-Cx) displays a unique anabolic effect on bone. Our aim was to assess the changes in cardiovascular and bone turnover markers from the oral intake of β-Cx and PS in post-menopausal women. Methods and results A randomized, double-blind, crossover study with β-Cx (0.75 mg/day) and PS (1.5 g/day), single and combined, was performed in 38 postmenopausal women. Diet was supplemented with 1 × 250 mL milk-based fruit drink/day for 4 weeks with a wash-out period of 4-weeks in between. Ser…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCampesterolOsteoporosisHypercholesterolemiaMedicine (miscellaneous)Parathyroid hormoneAdministration OralGastroenterologyBone and BonesBone remodelingchemistry.chemical_compoundDouble-Blind MethodRisk FactorsInternal medicineStatistical significancemedicineHumansCryptoxanthinsTriglyceridesAgedNutrition and DieteticsCross-Over StudiesDose-Response Relationship Drugbusiness.industryCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseCrossover studySitosterolsHealthy VolunteersClinical trialPostmenopauseEndocrinologyCholesterolTreatment OutcomechemistrySelective estrogen receptor modulatorCardiovascular DiseasesDietary SupplementsFemaleCardiology and Cardiovascular MedicinebusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Insulin Resistance and the Cardiometabolic Syndrome in HIV Infection

2009

Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of HIV-positive patients. However, long-term adverse effects of this therapy include dyslipidemia, insulin resistance (IR), changes in body fat distribution (lipodystrophy), and cardiometabolic syndrome (CMS). IR in HIV-positive patients does not seem to represent a significant independent risk factor for the development of cardiovascular disease; nevertheless, the association with other metabolic complications (dyslipidemia, fat redistribution) and CMS may increase the risk of type 2 diabetes and cardiovascular disease. The use of nucleoside analogue reverse transcriptase inhibitors is associated with the …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHIV InfectionsType 2 diabetesGastroenterologyInsulin resistanceAntiretroviral Therapy Highly ActiveDiabetes mellitusInternal medicineInternal MedicinemedicineHumansRisk factorMetabolic Syndromebusiness.industrymedicine.diseaseMetforminEndocrinologyCardiovascular DiseasesInsulin ResistanceLipodystrophyCardiology and Cardiovascular MedicinebusinessRosiglitazoneDyslipidemiamedicine.drugJournal of the CardioMetabolic Syndrome
researchProduct

Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C

2021

INTRODUCTION: In the last years the Hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. EVIDENCE ACQUISITION: We searched PubMed for articles published between January 1, 1995, through December 31, 2020, in English language. EVIDENCE SYNTHESIS: Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogeni…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHepatitis C virusMEDLINEHepacivirusDiseaseDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsVirusInternal medicineInternal MedicinemedicineHumansHepatitis chronic Cardiovascular diseases Antiviral agentsIn patientbusiness.industryPublic healthGastroenterologyvirus diseasesHepatitis C Chronicdigestive system diseasesChronic infectionCardiovascular DiseasesPersistent Infectionbusiness
researchProduct

Fasting-mimicking diet prevents high-fat diet effect on cardiometabolic risk and lifespan

2021

Diet-induced obesity is a major risk factor for metabolic syndrome, diabetes and cardiovascular disease. Here, we show that a 5-d fasting-mimicking diet (FMD), administered every 4 weeks for a period of 2 years, ameliorates the detrimental changes caused by consumption of a high-fat, high-calorie diet (HFCD) in female mice. We demonstrate that monthly FMD cycles inhibit HFCD-mediated obesity by reducing the accumulation of visceral and subcutaneous fat without causing loss of lean body mass. FMD cycles increase cardiac vascularity and function and resistance to cardiotoxins, prevent HFCD-dependent hyperglycaemia, hypercholesterolaemia and hyperleptinaemia and ameliorate impaired glucose and…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLongevityDiet High-FatMiceVascularityMetabolic DiseasesPhysiology (medical)Internal medicineDiabetes mellitusKetogenesisInternal MedicineMedicineAnimalsRisk factorCardiometabolic Riskbusiness.industrySettore BIO/16 - Anatomia UmanaCell BiologyFastingmedicine.diseaseObesityEndocrinologyAgeingCardiovascular DiseasesLean body massFemaleMetabolic syndromemedicine.symptombusiness
researchProduct

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality.

2014

High-density lipoprotein (HDL) particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wal…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismRVX 208BiologyBioinformaticschemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicinemedicineHumansEndothelial dysfunctionLiver X receptorDyslipidemiasTherapies InvestigationalReverse cholesterol transportCholesterol HDLGenetic Therapymedicine.diseaseUp-RegulationEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Farnesoid X receptorLipoproteinBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

Effects of alcohol-free beer on lipid profile and parameters of oxidative stress and inflammation in elderly women

2009

We assessed the influence of alcohol-free beer on factors implicated in atherosclerosis, such as lipid profile, oxidative stress parameters, and proinflammatory cytokines, in postmenopausal women, a population particularly at risk for atherosclerotic disease.The study was carried out in 29 nuns, 58 to 73 y old, who live in a convent with a disciplined, regular, and homogeneous lifestyle. The nuns maintained their habits and diet routine, but their meals were supplemented with 500 mL/d of alcohol-free beer (0.0%) divided into two doses over a 45-d period. Lipid profile, inflammatory markers such as C-reactive protein, interleukins 1 and 6, and tumor necrosis factor-alpha, and parameters of o…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPopulationInflammationmedicine.disease_causeThiobarbituric Acid Reactive SubstancesProinflammatory cytokineBeveragesLipid peroxidationchemistry.chemical_compoundInternal medicineHumansMedicineeducationInflammationeducation.field_of_studyNutrition and DieteticsEthanolmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryCholesterolInterleukinsVitamin EBeerMiddle AgedLipidsPostmenopauseOxidative StressC-Reactive ProteinEndocrinologychemistryCardiovascular DiseasesFemaleLipid PeroxidationInflammation Mediatorsmedicine.symptombusinessLipid profileOxidation-ReductionBiomarkersOxidative stressNutrition
researchProduct